Doripenem
|
|
Doripenem
|
| Systematic (IUPAC) name |
(4R,5S,6S)-6-(1-hydroxyethyl)-4-methyl-7-oxo-3-
[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]
sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
| Identifiers |
| CAS number |
148016-81-3 |
| ATC code |
? |
| PubChem |
73303 |
| Chemical data |
| Formula |
C15H24N4O6S2 |
| Mol. mass |
420.50426 g/mol |
| Pharmacokinetic data |
| Bioavailability |
? |
| Metabolism |
Renal |
| Half life |
? |
| Excretion |
? |
| Therapeutic considerations |
| Pregnancy cat. |
?
|
| Legal status |
|
| Routes |
IM, IV |
Doripenem is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup of carbapenems. It was launched by Shionogi Co. of Japan under the brand name Finibax in 2005. It is particularly active against Pseudomonas aeruginosa.
Doripenem was approved by the United States Food and Drug Administration on October 12, 2007, to be sold under the tradename Doribax.[1]
References
- ^ U.S. Food and Drug Administration (October 17 2007). "FDA Approves New Drug to Treat Complicated Urinary Tract and Intra-Abdominal Infections". Press release. Retrieved on 2007-10-25.
|
Antibacterials for systemic use: beta-lactam antibiotics - cephalosporins and related (J01D) |
| First generation |
Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazolin, Cefradine, Cefroxadine, Ceftezole |
| Second generation |
Cefaclor, Cefamandole, Cefmetazole, Cefonicid, Ceforanide, Cefotiam, Cefprozil, Cefuroxime |
| Third generation |
Cefdinir, Cefditoren, Cefetamet, Cefixime, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpiramide, Cefpodoxime, Cefsulodin, Ceftazidime, Ceftibuten, Ceftizoxime, Ceftriaxone, Latamoxef |
| Fourth generation |
Cefepime, Cefpirome, Cefquinome |
| Other beta-lactam antibacterials |
Monobactams (Aztreonam), Carbapenems (Meropenem, Ertapenem, Imipenem, Doripenem) |
|
Top